Community/Retail

Dr. Christina Madison, speaks with Dr. Jade Ranger, from the Prescription Shoppe in this episode of Public Health matters.

Tirzepatide is already approved under the brand name Mounjaro (Lilly) to be used along with diet and exercise to improve blood sugar in adults with type 2 diabetes.

Changes in gene expression could ultimately boost the production of inflammatory cytokines.

It's key for clinicians to optimize therapy prior to systemic agents.

More individuals who used e-cigarettes have reported pulmonary diseases compared with those who never smoked, including asthma.

Regular usage of cannabis may increase the risk of heart failure, stroke, or heart attack, even after adjusting for other cardiovascular disease risk factors.

TAK-279 is an investigational oral allosteric tyrosine kinase 2 inhibitor for active psoriatic arthritis.

Pricing is also a key issue, as many insurance plans do not cover these medications’ use for obesity.

With the rest of the retail world catching up with pharmacy queuing, will it change customer expectations at the counter?

With appointment-based models in community pharmacy, researchers have noted that community pharmacies are well suited for identifying and addressing social determinants of health.

Investigators found that there was no association of dementia incidence in insulin use at 5 years after stopping metformin and an association at 0.07 years for HbA1C level at year 1.

In May 2023, the FDA approved brexpiprazole as the first and only drug to receive approval for treatment of agitation associated with Alzheimer Disease dementia.

AI is expected to significantly quicken the pace of drug design and development, while improving the success rate of new medicines.

Pharmacists can play a vital role in educating patients about headaches and can help to limit their impact on the patient.

Treatment options for individuals impacted with PMS can vary and include lifestyle modifications, medication treatments, and herbal products.

Individuals that are younger in age, Black, have low levels of education, and low income were associated with a lower chance of getting the flu shot each year.

Ronna Hauser from the National Community Pharmacists Association (NCPA), discusses updates regarding reimbursement, pharmacy benefit manager (PBM) reforms, and direct and indirect remuneration (DIR) fees.

Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.

Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.

Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.

Pneumococcal serotype 3 was prevalent regardless of vaccination status, with the most common cases being in those with chronic lung disease.

It is crucial to continue to evolve from dependent prescribing to an independent model, and address barriers with opportunities for change.

In most patients who are pregnant or may become pregnant, warfarin is contraindicated due to increased risk of adverse fetal outcomes.

Texting with patients can help to improve pharmacy processes while creating better user experiences.

How pharmacy teams can remove cost barriers to cardiac care.

Preclinical studies and clinical trials have shown that both corticosteroids and VEGF inhibitors can be delivered as nanoparticles.

This “refreshing alternative” to calorie restriction does not include calorie counting, yet it is naturally associated with greater energy restriction compared to the latter.

Without policies to reduce greenhouse gas emissions, the number of cardiovascular-related deaths due to extreme heat could even triple by mid-century.

Study also showed that 76% of individuals treated with lecanemab-irmb had no deterioration in the tau positron emission tomography (PET) subset.

The approval is supported by safety data from clinical trials assessing abatacept in the treatment of patients aged 2 to 17 with psoriatic arthritis.